Traveller's diarrhoea vaccine - Scandinavian Biopharma

Drug Profile

Traveller's diarrhoea vaccine - Scandinavian Biopharma

Alternative Names: Enterotoxigenic Escherichia coli vaccine - Scandinavian Biopharma; ETEC vaccine - Scandinavian Biopharma; Etvax

Latest Information Update: 29 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Scandinavian Biopharma
  • Developer PATH; Scandinavian Biopharma
  • Class Bacterial vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Traveller's diarrhoea

Most Recent Events

  • 29 Jul 2017 Scandinavian Biopharma completes a phase I/II trial in Traveller's diarrhoea (In adolescents, In adults, In children, In infants, In volunteers) in Bangladesh (PO) (NCT02531802)
  • 08 May 2017 Phase-II clinical trials in Traveller's diarrhoea (Prevention, In volunteers) in Finland (PO) (EudraCT2016-002690-35)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Traveller's-diarrhoea(Prevention, In volunteers) in Sweden (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top